Protein kinase A determines platelet life span and survival by regulating apoptosis

Lili Zhao, … , Changgeng Ruan, Kesheng Dai

*J Clin Invest.* 2017. [https://doi.org/10.1172/JCI95109.](https://doi.org/10.1172/JCI95109)

Apoptosis delimits platelet life span in the circulation and leads to storage lesion, which severely limits the shelf life of stored platelets. Moreover, accumulating evidence indicates that platelet apoptosis provoked by various pathological stimuli results in thrombocytopenia in many common diseases. However, little is known about how platelet apoptosis is initiated or regulated. Here, we show that PKA activity is markedly reduced in platelets aged in vitro, stored platelets, and platelets from patients with immune thrombocytopenia (ITP), diabetes, and bacterial infections. Inhibition or genetic ablation of PKA provoked intrinsic programmed platelet apoptosis in vitro and rapid platelet clearance in vivo. PKA inhibition resulted in dephosphorylation of the proapoptotic protein BAD at Ser155, resulting in sequestration of prosurvival protein BCL-XL in mitochondria and subsequent apoptosis. Notably, PKA activation protected platelets from apoptosis induced by storage or pathological stimuli and elevated peripheral platelet levels in normal mice and in a murine model of ITP. Therefore, these findings identify PKA as a homeostatic regulator of platelet apoptosis that determines platelet life span and survival. Furthermore, these results suggest that regulation of PKA activity represents a promising strategy for extending platelet shelf life and has profound implications for the treatment of platelet number-related diseases and disorders.

Find the latest version:

http://jci.me/95109/pdf
Protein kinase A determines platelet life span and survival by regulating apoptosis

Lili Zhao,1 Jun Liu,1 Chunyan He,2 Rong Yan,1 Kangxi Zhou,1 Qingya Cui,1 Xingjun Meng,1 Xiaodong Li,1 Yang Zhang,1 Yumei Nie,1 Yang Zhang,1 Renping Hu,1 Yancai Liu,1 Lian Zhao,1 Mengxing Chen,1 Weiling Xiao,1 Jinglan Tian,1 Yunxiao Zhao,1 Lijuan Cao,1 Ling Zhou,1 Anning Lin,3 Changgeng Ruan,1 and Kesheng Dai1

Introduction

Platelets are the central regulator for keeping the vital balance between thrombosis and hemorrhage in the circulation and, simultaneously, play essential roles in many important pathophysiological processes, such as atherosclerosis, immune response, infections, and tumor progression and metastasis. However, platelets have very short life spans, and the mystery of platelets present in the circulation for only 8 to 9 days has puzzled human beings for more than half a century (1). More importantly, thrombocytopenia, which can cause life-threatening hemorrhage, often occurs in many common diseases, such as infections (2, 3), immune thrombocytopenia (ITP), diabetes, and bacterial infections. Inhibition or genetic ablation of platelets has been shown to limit the life of stored platelets, which are the best substance for the treatment of platelet number-related diseases and disorders.

Apoptosis delimits platelet life span in the circulation and leads to storage lesion, which severely limits the shelf life of stored platelets. Moreover, accumulating evidence indicates that platelet apoptosis provoked by various pathological stimuli results in thrombocytopenia in many common diseases. However, little is known about how platelet apoptosis is initiated or regulated. Here, we show that PKA activity is markedly reduced in platelets aged in vitro, stored platelets, and platelets from patients with immune thrombocytopenia (ITP), diabetes, and bacterial infections. Inhibition or genetic ablation of PKA provoked intrinsic programmed platelet apoptosis in vitro and rapid platelet clearance in vivo. PKA inhibition resulted in dephosphorylation of the proapoptotic protein BAD at Ser155, resulting in sequestration of prosurvival protein BCL-XL in mitochondria and subsequent apoptosis. Notably, PKA activation protected platelets from apoptosis induced by storage or pathological stimuli and elevated peripheral platelet levels in normal mice and in a murine model of ITP. Therefore, these findings identify PKA as a homeostatic regulator of platelet apoptosis that determines platelet life span and survival. Furthermore, these results suggest that regulation of PKA activity represents a promising strategy for extending platelet shelf life and has profound implications for the treatment of platelet number-related diseases and disorders.

Authorship note: Lili Zhao, J. Liu, C. He, and R. Yan contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: May 15, 2017; Accepted: September 21, 2017.
Reference information: J Clin Invest. https://doi.org/10.1172/JCI95109.

jci.org
patients with ITP, diabetes, and sepsis. Inhibition of PKA causes intrinsically programmed platelet apoptosis in vitro and acute platelet depletion in vivo. More importantly, activation of PKA protects platelets from apoptosis and clearance induced by storage or pathological stimuli. We conclude that PKA is a homeostatic regulator of apoptosis that determines platelet life span and survival under physiological and pathological conditions.

Results
PKA activity is markedly reduced in in vitro–aged and stored platelets or platelets from patients with ITP, diabetes, and sepsis. Apoptosis delimits platelet life span (6, 8, 18); however, how apoptosis is regulated remains unclear. We hypothesized that PKA involves regulating platelet apoptosis. Platelet-rich plasma (PRP) was incubated at 22°C for indicated times. Representative immunoblots and quantification for pGPIbβ (C) and PKA activity (D) are shown. Data are expressed as mean ± SD from 4 independent experiments. **P < 0.01 compared with controls. Student’s t test. (E–J) Platelets were isolated from patients with ITP (E and F), diabetes (G and H), and sepsis (I and J) and age- and sex-matched healthy controls. Representative immunoblots and quantification for pGPIbβ (E, G, and I) and PKA activity (F, H, and J) are shown. Data in each figure are expressed as mean ± SD from 6 patients and controls. *P < 0.05; **P < 0.01; #P < 0.001, compared with controls, Student’s t test. (K and L) Washed platelets were incubated with indicated bacteria (1:20) or vehicle control at 37°C for 90 minutes. Representative immunoblots and quantification for pGPIbβ (K) and PKA activity (L) are shown. Data are expressed as mean ± SD from 4 independent experiments. *P < 0.05; **P < 0.01, compared with control, Student’s t test.
levels of thrombin were obviously elevated in the plasma from the 3 kinds of patients (Figure 2A). To further investigate the role of thrombin in regulating PKA activity, different concentrations of thrombin were incubated with platelets. We found that relatively lower concentration of thrombin (less than 0.2 U/ml) induced apoptotic events in platelets (Figure 2, B and C) and that PKA activity was dose-dependently reduced by thrombin (Figure 2, D and E). In contrast, PKA activator (forskolin) markedly reduced apoptotic events in platelets stimulated by thrombin (Supplemental Figure 6). Therefore, these data demonstrate the role of thrombin in regulating PKA activity and apoptosis in platelets. However, higher concentration of thrombin (higher than 0.4 U/ml) activated platelets and elevated PKA activity synchronously (Supplemental Figure 7).

**Inhibition of PKA incurs intrinsic pathway of platelet apoptosis.** Next, we investigated the role of PKA in platelet apoptosis. As previously reported, platelet apoptosis is a mitochondria-mediated intrinsic form of programmed cell death (6, 7). Upon apoptotic stimulation, BCL-2 family proteins interact with the mitochondrial outer membrane, leading to transmembrane potential ($\Delta \Psi_m$) depolarization as well as activation of caspases (27, 28). We found that PKA inhibitor H89 dose-dependently induced $\Delta \Psi_m$ depolarization in platelets (Figure 3A). To exclude nonspecific effects of H89, a PKA-specific inhibitor, Rp-cAMPS, was incubated with platelets, and a similar effect was observed (Supplemental Figure 8). Immunoblots show that H89 activated caspase-3 in a dose-dependent manner (Figure 3B). We examined caspase-3 activity directly and found that caspase-3 activity was elevated by H89 treatment (Figure 3C). Caspases and other apoptogenic enzymes should disrupt plasma membrane integrity, leading to phosphatidylserine (PS) externalization and typical morphological alterations during apoptosis (29, 30). We found that H89 (Figure 3D) and Rp-cAMPS (Supplemental Figure 8) incurred PS externalization. Figure 3E shows that H89 induced platelet shrinkage in a dose-dependent manner. Scanning electron microscope images directly show that H89 dose-dependently induced shrinkage, filopod extrusion, and blebbing of plasma membrane (Figure 3F). H89 also induced apoptotic events in a time-dependent manner (Supplemental Figure 9). In addition, we found that PKA activator forskolin markedly decreased H89-induced platelet apoptotic events (Supplemental Figure 10). Together, these data demonstrate that the PKA inhibitors elicit intrinsic programmed platelet apoptosis.

**PKA-deficient platelets in conditional PKA Ca-KO mice undergo apoptosis.** We next confirmed the role of PKA in platelet apo-
The concentration (Supplemental Table 4). There was not any spontaneous bleeding tendency or thrombotic events over the life spans of PKA–/– and PKA–/+ mice. We found that ΔΨm-depolarized (Figure 4C) and shrunk (Figure 4D) platelets were obviously increased in PKA–/– mice. Scanning electron microscope images illustrate that the PKA–/– platelets presented shrinkage and blebbing of plasma membrane (Figure 4E), indicating that these platelets were undergoing apoptosis. PKA activity and the platelet counts of PKA+/– mice were not significantly different from those of PKA++ mice (Figure 4, B and F), suggesting that there might be a compensatory mechanism.

**Figure 3.** Inhibition of PKA induces platelet apoptosis. (**A**) Representative flow cytometric figures (left) and quantification (right) of ΔΨm depolarization of platelets incubated with H89 or vehicle at 22°C for 160 minutes (mean ± SD, n = 4). *P < 0.05 compared with control, 1-way ANOVA. (**B** and **C**) Western blot analysis with anti–caspase-3 or anti-gelsolin antibodies (**B**) and caspase-3 activity analysis (**C**) in platelets incubated with H89 or vehicle at 22°C for 30 minutes (n = 4). *P < 0.05 compared with control, Student’s t test. (**D**) Representative flow cytometric figures (left) and quantification of mean forward scatter (right) of platelets incubated with H89, vehicle, or A23187 at 22°C for 30 minutes (mean ± SD, n = 4). *P < 0.05 compared with control, 1-way ANOVA. (**F**) Representative scanning electron microscopy images of platelets treated with H89 at 22°C for 160 minutes are shown (n = 3). Scale bar: 1 μm.

tosis with genetic ablation mice. Since conventional PKA KO was lethal (11), we generated PF4-Cre-driven megakaryocyte- and platelet-targeted Pkaca (encoding PKA Cα) gene deletion mice (Figure 4A and Supplemental Figure 11). The deficiency of Pkaca and reduced PKA activity detected by dephosphorylated GPIbβ Ser166 and BAD Ser155 in the platelets were examined by Western blot (Figure 4B). The homozygous Pkacafl/flPf4-Cre (PKA–/–), heterozygous Pkacafl/+Pf4-Cre (PKA–/+), and Pkacafl/flPf4-Cre (PKA++), expressing normal levels of PKA Cα) mice did not differ in the number of red and white blood cells and hemoglobin concentration (Supplemental Table 4). There was not any spontaneous bleeding tendency or thrombotic events over the life spans of PKA–/– and PKA–/+ mice. We found that ΔΨm-depolarized (Figure 4C) and shrunk (Figure 4D) platelets were obviously increased in PKA–/– mice. Scanning electron microscope images illustrate that the PKA–/– platelets presented shrinkage and blebbing of plasma membrane (Figure 4E), indicating that these platelets were undergoing apoptosis. PKA activity and the platelet counts of PKA–/+ mice were not significantly different from those of PKA++ mice (Figure 4, B and F), suggesting that there might be a compensatory mechanism.
However, injection of anti-platelet mixture antibody R300, which incurs platelet apoptosis (Supplemental Figure 12), induced more rapid platelet clearance in PKA+/– mice than in PKA+/+ mice (Figure 4G), suggesting that the PKA+/– platelets are more prone to apoptosis. It has been well established that apoptotic cells are rapidly cleared by phagocytes in vivo (31, 32). We found that the number of circulatory platelets was markedly reduced in the PKA+/– mice (Figure 4F) and the life span of PKA+/– platelets was obviously decreased (Figure 4H). However, the proportion of reticulated platelets was not significantly reduced in the PKA+/– mice (Supplemental Figure 13). Moreover, the number and morphology of megakaryocytes were not varied in the bone marrow of PKA+/– mice compared with that of the WT mice (Supplemental Figure 14). These data suggest that the reduced platelets resulted from apoptosis-induced platelet...
destruction. Collectively, these data further demonstrate that PKA deficiency incurs platelet apoptosis.

**PKA regulates platelet apoptosis via mediation of phosphorylation of BAD at Ser155.** We then explored the mechanism for PKA inhibition induced platelet apoptosis. PKA activity was reduced by the PKA inhibitor H89, as indicated by dephosphorylation of GPIbβ Ser166 (Figure 5A). Western blot analysis for BAD, BCL-XL, and 14-3-3 with various antibodies (C, D, and E) confirmed these findings. BAD was phosphorylated at Ser155 in H89-treated platelets (Figure 5A). In contrast, PKA activator forskolin enhanced BAD Ser155 phosphorylation (Figure 5B). Previous studies suggested that BAD Ser155 was the level of BIM was not obviously varied in the PKA inhibitor-treated platelets (Figure 5A). There is evidence that PKA inhibition promotes p53 expression and stability (34) and that phosphorylation of p53 inactivates BCL-XL, leading to platelet apoptosis (5, 35). However, neither p53 nor phosphorylated p53 was altered in the PKA inhibitor–treated platelets (Figure 5A).

We found that phosphorylation of BAD at Ser155 was dose-dependently reduced by the PKA inhibitor (Figure 5A). In contrast, the PKA activator forskolin enhanced BAD Ser155 phosphorylation (Figure 5B). Previous studies suggested that BAD Ser155 was

**Figure 5. PKA regulates platelet apoptosis via mediation of phosphorylation of BAD at Ser155.** (A) Washed platelets were incubated with indicated concentrations of H89 or vehicle at 22°C for 160 minutes. Western blot analysis for the levels of indicated proteins with different antibodies. (B and C) Washed platelets were incubated with H89 (25 μM), forskolin (10 μM), or vehicle at 22°C for 120 minutes. The platelets were lysed and centrifuged. Western blot analysis for the levels of indicated proteins with different antibodies (B). The lysates were immunoprecipitated with anti-BAD antibody overnight. Western blot analysis for BAD, BCL-XL, and 14-3-3 with various antibodies (C). (D and E) Washed platelets were incubated with H89 (25 μM), forskolin (10 μM), or vehicle at 22°C for 120 minutes. The mitochondria of the pretreated platelets were isolated and verified as described in Methods. Representative images of mitochondria stained for BAD and BCL-XL are shown. Scale bar: 5 μm (D). Western blot analysis for BAD and BCL-XL in the mitochondria, and quantification of the levels of BAD and BCL-XL from the Western blot data (E). Data are expressed as mean ± SD (n = 5). *P < 0.001, 1-way ANOVA. The blots and images shown in each panel are representative of at least 5 separate experiments with different donors. (F) Schematic representation of proposed mechanism for PKA-regulated platelet apoptosis. Thrombin generated in the circulation (or in the absence of endothelium-derived PGI₂) reduces PKA activity. The decrease of PKA activity results in dephosphorylation of BAD at Ser155, which releases 14-3-3 and sequesters prosurvival BCL-XL on mitochondria, leading to apoptosis.
The Journal of Clinical Investigation

RESEARCH ARTICLE

phosphorylated by PKA, which prevents it from binding to BCL-XL via enhancement of 14-3-3 association (36, 37). We found that the association of BAD with BCL-XL was markedly enhanced or reduced by H89 or forskolin, respectively. In contrast, binding of 14-3-3 with BAD was reduced by H89 and increased by forskolin, in contrast with what occurred with BCL-XL (Figure 5C). These data suggest that the PKA inhibitor H89 (or forskolin) inactivates (or activates) prosurvival BCL-XL via regulation of the association of BAD with BCL-XL. Using confocal microscopy, we demonstrate that BAD colocalized with BCL-XL to mitochondria (Figure 5D). H89 enhanced, but forskolin reduced, localization of BAD to mitochondria (Figure 5, D and E). As is known, nonphosphorylated BAD heterodimerized with BCL-XL on mitochondria, thereby releasing the proapoptotic BAX and leading to apoptosis (36–39). Therefore, our results suggest that PKA inhibition results in dephosphorylation of BAD at Ser155, which sequesters prosurvival BCL-XL on mitochondria, leading to apoptosis (Figure 5F). In support of this model, we found that PKA inhibitor H89–induced apoptotic events were markedly decreased in Bad−/− mice treated with Rp-cAMPs (Supplemental Figure 15). However, compared with those in WT mice, peripheral platelets were markedly elevated in the PKA−/− mice treated with Rp-cAMPs (Supplemental Figure 16). Platelet counts began to recover after 8 hours and reached normal levels at around 36 hours after injection of Rp-cAMPs. The left panels show representative flow cytometric profiles of thiazole-orange–stained platelets prior to or 8 hours after injection of Rp-cAMPs. The right panel shows the number of platelets (left axis) and reticulated platelets (right axis) before and after injection of Rp-cAMPs. (A and B) Male ICR mice were injected with a single dose of Rp-cAMPs (50 mg/kg) through the tail vein. Platelet counts (A and B) and reticulated platelet counts (B) were determined at the indicated time points. *P < 0.001, compared with control, 2-way ANOVA. (C) Male ICR mice were intraperitoneally injected with a single dose of anti-platelet antibody (R300, 0.15 mg/kg) to synchronize platelet production. The antibody induced severe thrombocytopenia. The newly synthesized platelets were released into the circulation, as indicated by reticulated platelets (right axis) increasing. The number of platelets (left axis) became stable from day 4. (D and E) Male ICR mice were intraperitoneally injected with a single dose of anti-platelet antibody (R300, 0.2 mg/kg) and then injected with Rp-cAMPs (50 mg/kg) through the tail vein on days 2 or 7, respectively. Reticulated platelet counts (D) and platelet counts (E) were determined prior to or 8 hours after injection of Rp-cAMPs. (F and G) Male ICR mice were injected with PKA activator 8-Br-cAMP (2.5 mg/kg) or vehicle control (PBS) through the tail vein. Platelet counts (F) and reticulated platelet counts (G) were determined at day 8. Data in each panel represent mean ± SD of 5 to 6 mice at each time point. *P < 0.05; **P < 0.01; ***P < 0.001, compared with control, Student’s t test (D–G).

PKA inhibitor causes acute thrombocytopenia. PKA inhibition results in platelet apoptosis in vitro. Thus, we reasoned that PKA inhibitor may shorten platelet life span in vivo. As expected, after intravenously injecting a single dose of PKA inhibitor Rp-cAMPs, platelet counts began to drop in 30 minutes and dropped to a nadir of around 70% at 8 hours (Figure 6A). Rp-cAMPs caused thrombocytopenia in a dose-dependent manner (data not shown). However, compared with those in WT mice, peripheral platelets were markedly elevated in the PKA−/− mice treated with Rp-cAMPs (Supplemental Figure 16). Platelet counts began to recover after 8 hours and reached normal levels at around 36 hours after injection (Figure 6B). These data indicate that reduction of PKA activity shortens the life span of peripheral platelets. In addition, Bad deficiency rescued Rp-cAMPs–induced platelet clearance (Supplemental Figure 17), further demonstrating that PKA regulates platelet life span via BAD-mediated platelet apoptosis.

Interestingly, with the decrease of platelet counts, reticulated platelets began to increase (Figure 6B), suggesting that the younger platelets are resistant to PKA inhibitor–induced apoptosis. This finding is consistent with the data showing that apoptosis occurred in aged or stored platelets (Figure 1, A and B). To further investigate whether the older platelets are more susceptible to PKA inhibition–induced clearance in vivo, anti-platelet mixed antibodies (R300), which incur platelet clearance in mice (40), were injected into mice to artificially synchronize platelet production. Almost no platelets were detected in peripheral blood after 1 day of R300 injection, and the platelet numbers recovered within 7 days (Figure 6C). During this period, reticulated platelets increased sharply...
Activation of PKA protects stored platelets from apoptosis, clearance, and loss of function. (A and B) ΔΨ_m depolarization and PS exposure of human platelets incubated with H89 (25 μM), forskolin (5 μM), or vehicle at 22°C for indicated times. Data are represented as mean ± SD from 4 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001, 2-way ANOVA. (C) Mouse platelets were incubated with H89 (25 μM), forskolin (5 μM), or vehicle at 22°C for 72 hours. The platelets were labeled with calcein and injected into ICR mice (n = 5). The percentage of calcein-labeled platelets remaining in circulation was determined by flow cytometry. Data are represented as mean of normalized percentage of calcein-labeled platelets (time point 0 = 100%) ± SD of 3 independent experiments. **P < 0.01; ***P < 0.001, 2-way ANOVA. (D and E) Human washed platelets were incubated with forskolin (5 μM) or vehicle (DMSO) at 22°C for 72 hours. The pretreated washed platelets were stimulated with ristocetin (1.25 mg/ml) plus von Willebrand factor (7.5 μg/ml) (D) and collagen (5 μg/ml) (E) at 37°C under constant stirring. Platelet aggregation was recorded in a CHRONO-LOG aggregometer. Histograms of maximal platelet aggregation under the indicated conditions are shown as mean of 5 independent experiments. **P < 0.01, Student’s t test. (F) Washed mouse platelets were incubated with forskolin (5 μM) or vehicle (DMSO) at 22°C for 72 hours and were labeled with calcein-AM (5 μg/ml). The recipient mice were injected intravenously with pretreated platelets (5 × 10^7/g). FeCl_3-induced thrombosis in the mice was recorded by real-time microscopy at 3 minutes. Only forskolin-treated calcein-AM-labeled platelets were detected in the thrombus. No H89-treated or vehicle control-treated (DMSO) stored platelets were found in the thrombus. Each image is representative of 5 mice. Original magnification ×200 (×10 eyepiece, ×20 objective).
In addition to apoptosis, there are other kinds of storage lesions (41), contributing to clearance of transfused platelets. We therefore investigated whether prevention of platelet apoptosis by PKA activation could rescue stored platelets from rapid clearance in mice. Similar to the findings with human platelets, PKA inhibitor H89 promoted, but PKA stimulator forskolin reduced, apoptotic events in stored mouse platelets (data not shown). Notably, forskolin obviously protected the stored platelets from clearance in vivo; in contrast, H89 accelerated the clearance (Figure 7C). Moreover, unlike vehicle-treated platelets, forskolin-treated stored platelets retained the functions of aggregation in vitro (Figure 7, D and E) and thrombosis formation in vivo (Figure 7F). These data demonstrate that PKA activator protects platelets from apoptosis in vitro and prevents transfused platelet clearance in vivo.

**PKA activation protects pathologically stimulated platelets from apoptosis in vitro and clearance in vivo.** Autoantibody-induced platelet apoptosis results in rapid platelet destruction in ITP patients (4, 42). Therefore, incubation of normal platelets with serum from ITP patients that contains autoantibodies induced platelet apoptosis (Figure 8, A and B). However, preincubation of platelets with forskolin markedly reduced apoptotic events in the serum-treated platelets (Figure 8, A and B). To further investigate the effect of the PKA activator on antibody-induced platelet clearance in vivo, we set up a murine model of ITP. The Journal of Clinical Investigation

![Figure 8](image)

**Figure 8. PKA activation protects pathologically stimulated platelets from apoptosis in vitro and clearance in vivo.** (A and B) Washed human platelets were incubated with forskolin (20 μM) or vehicle at 37°C for 30 minutes and further incubated with serum from ITP patients or healthy controls (1:1 volume) for 12 hours. ΔΨm Depolarization (A) and PS exposure (B) are shown. *P < 0.05; **P < 0.01; Mann-Whitney U test for control versus ITP. (**P < 0.01; *P < 0.01, Wilcoxon matched-pairs signed rank test for ITP versus ITP plus forskolin. (C) ICR mice were injected with 8-Br-cAMP or vehicle and further injected with 2.4G2. After 10 minutes, R300 was injected into the mice (n = 6). Data are presented as mean of normalized platelet counts (time point 0: 100%) ± SD from 3 independent experiments. *P < 0.05; **P < 0.001, Wilcoxon matched-pairs signed rank test for control versus ITP plus forskolin. (D) Human platelets were incubated with forskolin and serum from diabetes patients or healthy controls. *P < 0.05, Student’s t test.

**Discussion**

In this study, we show that PKA activity is markedly reduced in in vitro–aged platelets or platelets from patients with ITP, sepsis, or diabetes. Inhibition or genetic deletion of PKA incurs intrinsic programmed platelet apoptosis in vitro and rapid platelet clearance in vivo. We demonstrate that PKA regulates platelet apoptosis through mediating BAD Ser155 phosphorylation. Notably, activation of PKA protects platelets from apoptosis induced by storage and pathological stimuli in vitro and elevates peripheral platelets in vivo.

Strikingly, we found that PKA activity was reduced in platelets during storage and in platelets from different patients. PKA activity is mainly regulated by cAMP, the level of which is determined by adenylate cyclase (12) and phosphodiesterases (13) in platelets. Endothelium-derived prostacyclin (PGI2) has been determined to the main physiologic stimulator of cAMP production through activation of adenylate cyclase in platelets, which are marginal-ized to the periphery of the vessel, facilitating constant exposure to PGI2 released by endothelial cells (Figure 5F) (43). PGI2 exists in plasma with a half-life of only 8.4 to 13.0 minutes, after which it is converted to an inactive stable form (44). Therefore, it is like-ly that the reduced PKA activity in stored platelets is, at least in part, caused by the absence of PGI2 stimulation. In support of this hypothesis, the addition of PKA activator protected stored platelets from apoptosis (Figure 7, A and B). Our findings suggest that...
trace amounts of thrombin generated in the circulation reduce PKA activity and result in platelet apoptosis in different patients. However, this suggestion does not exclude the possibility that some pathological stimuli induce platelet apoptosis through other mechanisms. For example, platelet apoptosis induced by anti-GPIIb antibodies was observed here and reported previously (42). Apoptotic platelets expose PS and release microparticles that incur a procoagulant profile, leading to generation of thrombin. The mutual promoted effects may explain the subtle balance between thrombosis and hemostasis in some diseases (e.g., ITP) and also suggest possible severe consequences once the balance is broken (e.g., disseminated intravascular coagulation).

We demonstrate that PKA regulates platelet apoptosis through regulation of the interaction of BAD with prosurvival BCL-XL. PKA inhibition resulted in dephosphorylation of BAD at Ser155, which released 14-3-3 and sequestered prosurvival BCL-XL on mitochondria, leading to apoptosis. In support of our observation, platelet life span was extended in Bad−KO mice, leading to a modest elevation of peripheral platelets (9). Our finding provides an explanation of the mechanism for this observation (Figure 5F).

We further demonstrate that Bad deficiency is protective against PKA inhibitors–induced platelet apoptosis in vitro (Supplemental Figure 15) and platelet clearance in vivo (Supplemental Figure 17). Moreover, consistent with our observations, the BH3 mimetic ABT-737, which has a binding profile similar to that of BAD (45), incurred platelet apoptosis in vitro and acute thrombocytopenia in vivo (6, 8). We demonstrate that PKA activator protect platelets from apoptosis induced by ABT-737 (Supplemental Figure 19).

BCL-XL has been found to play a key role in regulating platelet apoptosis (6). Degradation of BCL-XL in aged platelets was presumed to initiate apoptosis and determine platelet life span (6). Consistent with previous reports, we observed BCL-XL degradation in stored platelets. However, PKA activator prevented not only apoptosis in the stored platelets (Figure 7), but also BCL-XL degradation in the platelets (Supplemental Figure 20). In addition, no obvious BCL-XL degradation was observed in PKA inhibitor–induced acute platelet apoptosis (Figure 5). Apoptosis per se incurs proteolysis. Thus, our findings suggest that the decline of BCL-XL in apoptotic platelets might be a consequence rather than an initiator of apoptosis. Importantly, activation of PKA prevented apoptosis in aged platelets and protected platelets from apoptosis induced by pathological stimuli as well, suggesting that apoptosis initiated by ΔΨm depolarization is an irreversible process. Thus, these findings support PKA as an upstream regulator for initiating and regulating platelet apoptosis.

Apoptosis contributes to storage lesion, which severely limits platelet shelf life (6, 8, 21). Several groups have tried to reduce storage lesion by inhibiting apoptosis–related enzymes such as caspases. However, although the enzymes were inhibited, the alleviation for storage lesion was not significant. It is noteworthy that, despite the mechanism remaining unclear, inhibition of p38 MAPK (46) or p38 MAPK-mediated GPIIb shedding (46, 47) significantly improves the quality and posttransfusion survival and function of stored platelets. We and others previously reported that GPIIb-dependent signaling could induce platelet apoptosis and that association of 14-3-3 with the cytoplasmic domain of GPIIb is essential for apoptotic signaling (7, 48, 49). Storage incurs activation of p38 MAPK and p38 MAPK–mediated cytosolic phospholipase A2, resulting in release of arachidonic acid from membrane phospholipids, which transfers 14-3-3 to the cytoplasmic domain of GPIIbα (48, 49). In the meantime, p38 MAPK activates ADAM17, leading to GPIIb ectodomain shedding (47), which enhances GPIIbα clustering and association of 14-3-3 with the cytoplasmic domain of GPIIbα (50). 14-3-3 competes with BCL-XL to bind BAD, thus increasing 14-3-3–GPIIbα interaction (38, 39). Thus, elevation of 14-3-3–GPIIbα interaction should enhance sequestration of prosurvival BCL-XL by BAD on mitochondria, leading to platelet apoptosis. This hypothesis is supported by observations made in platelets rewarmed after cold storage, in which enhancement of 14-3-3–GPIIbα interaction reduced association of 14-3-3 with BAD, resulting in platelet apoptosis (50, 51). Therefore, the mechanism by which inhibition of p38 MAPK or GPIIbα shedding extends platelet shelf life is likely through the inhibition of 14-3-3–BCL-XL–BAD–mediated platelet apoptosis. In light of current findings, elevation of PKA activity, similar to the inhibition of p38 MAPK or GPIIbα shedding, may represent a strategy for preventing apoptosis and extending the shelf life of platelets.

Thrombocytopenia, which occurs with many diseases or during treatments, leads to life-threatening hemorrhage worldwide every day. However, the pathogenesis of thrombocytopenia is not yet fully understood, leading to difficulty in selecting appropriate treatment. For example, there are many refractory ITP patients who do not respond to conventional treatments, and the reason for this remains unclear (52). Similarly, little is known about the pathogenesis of thrombocytopenia during bacterial infections or diabetes (2, 3, 5). According to current observations, once thrombin is generated in the circulation, it should reduce PKA activity in platelets, leading to apoptosis and destruction. Thus, our finding appears to disclose a common pathogenesis of thrombocytopenia that occurred in all of the thrombin–generated diseases, including malignant, metabolic, and cardiovascular diseases. Furthermore, we found that PKA activation effectively protects platelets from apoptosis provoked by different stimulations and elevates peripheral platelets. Therefore, these findings suggest a profound therapeutic strategy for thrombocytopenia induced by different pathological stimuli. On the other hand, as PKA inhibition incurs platelet apoptosis and rapid clearance in vivo, targeting PKA appears to be a promising strategy for treating platelet–excessive or hyperactive diseases such as essential thrombocytosis and thrombosis.

In conclusion, our study identifies PKA as a homeostatic regulator of platelet apoptosis to determine platelet life span and survival. Regulation of PKA activity represents a strategy for extending platelet shelf life and has profound implications for the treatment of platelet number–related diseases.

**Methods**

*Patients and healthy volunteers.* Twenty-five subjects with ITP (Supplemental Table 1), 11 subjects with diabetes (Supplemental Table 2), 15 subjects with sepsis (Supplemental Table 3), and age- and sex–matched healthy control subjects were recruited for the studies.

*Mice.* PKA Cα conditional KO mice were generated by introducing a loxP site on either side of exons 6, 7, and 8 of the Pkaca gene (Figure 4A). For each targeting site, gRNAs were designed. gRNAs and Cas9...
mRNAs were transcribed by T7 RNA polymerase. The Phkaa-targeting gRNAs, Cas9 mRNAs, and donor DNAs with loxP-flanked targeted exons were microinjected into the 1-cell embryos to generate chimera. Targeted Phkaa floxed founder mice were identified by PCR and sequencing, and then these founder mice were bred to C57BL/6j mice to verify the germline transmission by PCR and sequencing (Supplemental Figure 11). Mice with KO specific to megakaryocytes and platelets were produced by crossing the floxed mice with transgenic mice expressing Pff4 promoter-driven Cre recombinase (008535, Pf4-Cre; The Jackson Laboratory). All of the KO processes were produced on a C57BL/6j background. Genotyping was performed by PCR, and Phkaa deficiency was verified by immunoblotting. Bad−/− mice were generated on a 129/SvJ background as described previously (53) and had been backcrossed to a C57BL/6 background for more than 10 generations. C57BL/6 WT mice and ICR WT mice were purchased from JOINN Laboratories. Male mice were analyzed at 6 to 12 weeks of age unless otherwise specified.

Antibodies and reagents. Antibodies against β-actin (catalog 4979), mouse PKA C-α (catalog 4782), p53 (catalog 2524), phospho-p53 (ser15) (catalog 9284), and human PKA C-α (catalog 2245) were from Cell Signaling Technology. Antibodies against BAD (ab32445), phospho-BAD (Ser155) (ab28825), CD16+CD32 (2.4G2) (ab210219), BCL-XL (sc-8392), BAK (sc-832) and BAX from BioLegend. Antibodies against caspase-3 (sc-271028), phospho-gated mouse anti-human P-selectin antibody (catalog 304904) and PE–anti-mouse CD41 antibody (catalog 133906) and FITC-conjugated anti-rabbit IgG (G4896), and anti-rabbit IgG H&L (Alexa Fluor 488) (ab150077), 555) (ab150114), anti-rabbit IgG H&L (Alexa Fluor 488) (ab150077), FITC-conjugated anti-CD41 antibody (ab19708), and Thrombin-antithrombin Complex ELISA Kit (ab108907) were from Abcam. Anti-phospho-GPIββ (Ser166) and anti-GPIββ antibodies were gifts from Xiaoping Du (University of Illinois at Chicago, Chicago, Illinois, USA) (20). N-[p-(Bromo Cinnamyl) amino]ethyl)-5-isouquinoline sulfonamide (H89) (S1644), cyclosporin A (S1563), JC-1 (C2005), caspase-3 activity assay kit (C1115), and forskolin (S1612) were from Sigma-Aldrich. Mitochondria Isolation Kit (catalog 89874) was from Thermo Fisher Scientific. Calcine AM was purchased from Dojindo Laboratories. Annexin V–FITC Kit (LHK601-100) was from BioLegend. α-Tubulin antibody (catalog 7597) was from ProSci. PE-anti-mouse CD41 antibody (catalog 133906) and FITC-conjugated mouse anti-human P-selectin antibody (catalog 304904) were from BioLegend. Antibodies against caspase-3 (sc-271028), phospho-BAD Ser155 (sc-133356), BCL-XL (sc-8392), BAK (sc-832) and BAX (sc-493), A23187 (sc-3591), Protein G Plus–agarose (sc-2002), Protein A/G Plus–agarose (sc-2003), mouse IgG (sc-2025), normal rabbit IgG (sc-2025), mouse PKA C-α (catalog 4782), p53 (catalog 2524), phospho-p53 (Ser166) and anti-GPIbα (C2005), caspase-3 activity assay kit (C1115), and forskolin (S1612) were purchased from Thermo Fisher Scientific. Calcein-AM was purchased from Dojindo Laboratories. Annexin V–FITC Kit (LHK601-100) was from Jiamay Technologies. Glutaraldehyde solution (G5882), thiazole orange (V900090), Antithrombin Complex Human ELISA Kit (ab108907) were from R&D Systems. Lactadherin (FF0805) was from Haematologics. Platelet counts and preparation. Platelet and blood cell counts were performed with Sysmex XP-100 Hematologic Analyzer (Sysmex Corporation). Blood was collected from the inferior vena cava and anticoagulated with 200 μl of 3.8% sodium citrate in 9 ml of heparinized saline. Blood samples were stored at –80°C before use. The amounts of bacteria were determined by a petri dish colony-counting method, and the corresponding concentrations of each bacterium were as follows: S. aureus, 1.65 × 10^12 CFU/ml; K. pneumoniae, 1.67 × 10^12 CFU/ml; E. coli, 1.71 × 10^10 CFU/ml; P. aeruginosa, 1.14 × 10^10 CFU/ml; E. faecalis, 2.00 × 10^10 CFU/ml and S. haemolyticus, 1.80 × 10^11 CFU/ml. Just before experiments, bacteria were centrifuged at 2,000 g for 5 minutes and resuspended in fresh LB media with 30% glycerin and stored at –80°C before use. The methods of bacterial transformation were performed as described (55). Briefly, whole blood was drawn from the inferior vena cava and anticoagulated with 1/7 volume of acid-citrate-dextrose (ACD) (2.5% trisodium citrate, 2.0% d-glucose, 1.5% citric acid). PRP was collected from the whole blood. PRP was centrifuged at 2,000 g for 5 minutes and resuspended in modified Tyrode’s buffer (MTB) (121.2 mM NaHCO3, 136.9 mM NaCl, 5.6 mM d-glucose, 2.6 mM KCl, 2.4 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, and 0.1% BSA, pH 7.4).

PCR genotyping. To genotype the weaned pups, genomic DNA was extracted from about 0.5 cm of mouse tail and analyzed by PCR and sequencing. The mice containing the floxed allele were identified by PCR and sequencing analysis using primers flanking the 5’ loxP site and 3’ loxP site. The sense loxP-F1 (5’-ATGTCCTACTATGTCAAGGCTCC-3’) and antisense loxP-R2 (5’-TCAATAGTGACTAAGGCTGGG-3’) flanking the 5’ loxP site amplify a 158-bp band from the WT allele and a 192-bp band from the floxed allele. The sense loxP-F1 (5’-ACGGATTTCAGCTCTGAAGGA-3’) and antisense loxP-R2 (5’-TAGTTGAGGCAATCAACCCCTGTC-3’) flanking the 3’ loxP site amplify a 216-bp band from the WT allele and a 250-bp band from the floxed allele. The sense PKA Cα-F (5’-GACACAGGGTCTCACCTTGTAG-3’) and antisense PKA Cα-R (5’-TAGTGTGGCCAGTCTCTGCAG-3’) flanking the 5’ and 3’ loxP sites were used to identify the correctness of both the 5’ loxP and 3’ loxP sequences. Mice containing the Cre allele were determined by the following primers: Cre sense: 5’-CCCATACAGCA-CCCTTTTG-3’ and antisense: 5’-TGCACACGTGACAGTT-3’; 450 bp band for Cre allele, no band for WT allele. PCR was performed as follows: briefly, in a 25 μl reaction volume, 100 ng of genomic DNA and 10 pmol of each primer (loxP-F1, loxP-R2, loxP-F2, loxP-R2, PKA-Cα-F, and PKA-Cα-R) were amplified in PCR buffer supplemented with 0.5 units of Taq polymerase (MightyAmp Takara). The cycling parameters were as follows: 98°C for 5 minutes; 32 cycles of 10 seconds at 98°C, 20 seconds at 60°C, and 1 minute at 68°C; and a final extension for 5 minutes at 68°C. 10 μl of each reaction mixture was separated on a 1.0% agarose gel in 1× Tris-acetate-EDTA buffer.

Bacterial culture and preparation. S. aureus (ATCC 29213), Klebsiella pneumoniae (ATCC 700603), E. coli DH5a, Pseudomonas aeruginosa (ATCC 27853), Enterococcus faecalis (ATCC 29212), and Staphylococcus haemolyticus (BD 3569) were obtained from the Clinical Laboratory of the Second Affiliated Hospital of Soochow University. All strains from frozen stocks were cultured in Luria-Bertani (LB) at 37°C for 15 hours.

Platelet counts and preparation. Platelet and blood cell counts were performed with Sysmex XP-100 Hematologic Analyzer (Sysmex Corporation). The platelets from healthy volunteers were prepared as previously described (7). Briefly, whole blood was drawn from the inferior vena cava and anticoagulated with 1/7 volume of acid-citrate-dextrose (ACD) (2.5% trisodium citrate, 2.0% d-glucose, 1.5% citric acid). PRP was collected from whole blood by 200 g centrifugation for 11 minutes. Platelets were washed twice with CGS buffer (0.123 M NaCl, 0.033 M d-glucose, 0.013 M trisodium citrate, pH 6.5), and resuspended in MTB to a final concentration of 3 × 10^11/ml. Then washed platelets were incubated at room temperature (RT) for 2 hours before use. For the preparation of mouse platelets, whole blood from mice was collected from the eye socket vein using 1/7 volume of ACD as anticoagulant. Platelets were washed with CGS buffer and resuspended in MTB to a concentration of 3 × 10^11/ml and allowed to incubate at 22°C for 1 to 2 hours. For the preparation of platelets from patients, whole blood was drawn from the inferior vena cava and anticoagulated with ACD. PRP was collected from the whole blood. PRP was centrifuged...
at 200 g for 2 minutes to separate plasma and platelets. Platelets were resuspended in MTB to a final concentration of 3 × 10^8/ml.

In vivo platelet experiments. C57BL/6 mice (6 to 8 weeks) or male ICR mice (4 to 5 weeks) were injected with different concentrations of PKA inhibitor (Rp-cAMPS), activator (8-Br-cAMP), or vehicle control (PBS) through the tail vein. In experiments with the mouse ITP model, male ICR mice (4 to 5 weeks) were intravenously injected with a single dose of PKA activator 8-Br-cAMP (0.625, 1.25, or 2.5 mg/kg) with or without intraperitoneal injection of anti-mouse CD16/CD32 antibody (2.4G2, 0.6 mg/kg) (BD) to block Fc-dependent clearance. After 10 minutes, the mice were intraperitoneally injected with anti-platelet antibody (R300, 0.1 mg/kg) or vehicle control. Whole blood was collected from eye socket veins at certain time points, and platelet count was performed with Sysmex XP-100 Hematologic Analyzer.

Platelet clearance. Washed mouse platelets in MTB (3 × 10^8/ml) were incubated with H89 (25 μM), forskolin (5 μM), and was incubated with 0.5 μl of H89 (25 μM), forskolin (5 μM), or vehicle control at different temperatures for different times. The lipophilic cationic probe JC-1 was added to the pretreated platelets to a final concentration of 2 μg/ml and incubated at 37°C in the dark for 5 minutes. The treated samples were detected by flow cytometry. Depolarization is characterized as the decrease in the content of JC-1 aggregates, as reflected in the decrease of FL2 fluorescence.

PS externalization assay. The pretreated platelets were mixed with annexin V-binding buffer and annexin V-FITC at a 1:50:1 ratio. Samples were gently mixed and incubated at RT for 15 minutes in the dark, then analyzed by flow cytometry. In some experiments, treated platelets were incubated with lactadherin to a final concentration of 5 μg/ml in the dark for 30 minutes, then analyzed by flow cytometry.

Caspase-3 activity assay. Platelets (3 × 10^8/ml) were incubated with H89 (25 μM) or DMSO at 22°C for 30 minutes. The caspase-3 activity assay was performed on 96-well microtiter plates by adding 10 μl of platelet lysate per sample in 80 μl reaction buffer and 10 μl caspase-3 substrate (Ac-DEVD-pNA, 2 mM). Samples were further incubated at 37°C for 4 hours and were determined by an ELISA reader at an absorbance of 405 nm. The specific activity of caspase-3, normalized for the total protein of the sample, was then indicated as fold of the baseline caspase-3 activity of the vehicle control-treated platelets.

Platelet shrinkage. Washed platelets were incubated with indicated concentrations of H89, vehicle control, or A23187 (positive control) at 22°C for 30 minutes. FITC-conjugated anti-CD41 antibody was mixed with pretreated platelets at a 1:10 ratio. Samples were gently mixed and incubated at RT for 10 minutes in the dark. Then platelets were fixed with 1% cold paraformaldehyde, further incubated at RT in the dark for 30 minutes, and analyzed by flow cytometry. After acquisition, FSC-FL1 dot plots were analyzed. Platelet shrinkage was determined by analyzing FSC dot plots as the decrease in FSC characteristics of CD41-positive events and expressed as the mean FSC. A23187 and DMSO were set as positive and negative controls, respectively.

Scanning electron microscopy of platelet morphology. Washed platelets (3 × 10^8/ml) were incubated with H89 or vehicle control (DMSO) at 37°C for 160 minutes. Then platelets were fixed at 30 minutes with 2.5% glutaraldehyde. Fixed platelets were gradually dehydrated in alcohol and acetone. Specimens were taken by acetonitrile freeze-vacuum-dry technique and glued on the sample table, then coated with gold in a vacuum sputter coater and scanned with a Philips XL-20 scanning electron microscope, whose accelerated voltage was 15.0 KV.

Isolated mitochondria from platelets. The mitochondria of platelets were isolated using the Mitochondria Isolation Kit (Thermo Fisher Scientific). Briefly, washed human platelets (3 × 10^8/ml) were incubated with H89 (25 μM) or forskolin (10 μM) at RT for 2 hours. Platelets were then suspended in mitochrondion isolation buffer A (400 μl) for 2 minutes, buffer B (5 μl) for 5 minutes, and buffer C (400 μl) for 2 minutes, followed by centrifugation. The supernatant was centrifuged at 12,000 g for 10 minutes. The pellet containing the mitochondria was washed with buffer C. The isolated mitochondria were verified and analyzed by Western blotting or confocal microscopy.

Confocal microscopy. Isolated mitochondria from platelets were fixed with 4% paraformaldehyde in PBS for 10 minutes and then permeabilized with 0.5% Triton-X 100 in PBS with 3% BSA for 10 minutes. The mitochondria were incubated with different antibodies, including rabbit monoclonal anti-BAD antibody (Abcam, ab32445) and mouse anti–BCL-XL antibody (Santa Cruz Biotechnology Inc., sc-8392) at 1:100 dilution in PBS with 10% BSA at 4°C overnight. The mitochondria were then washed and incubated with Alexa Fluor 555-conjugated anti-mouse IgG H&L (Abcam, ab150114) or Alexa Fluor...
488–conjugated anti-rabbit IgG H&L (Abcam, ab150077). The stained mitochondria were observed with a LEICA TCS SP8 confocal microscope with a x63 oil immersion lens.

**Western blots.** Washed platelets (3 × 10⁹/ml) were incubated with various concentrations of PKA activators, inhibitors, or vehicle control at 37°C or RT for indicated times and lysed with an equal volume of lysis buffer on ice for 30 minutes. Proteins were separated by SDS-PAGE. After blocking, membranes were incubated with primary antibodies and protein bands were visualized by the ECL Chemiluminescence System on Kodak film. Quantification was performed with ImageJ software (NIH).

**Commmunoprecipitation.** Washed platelets (3 × 10⁹/ml) were preincubated with PKA activators, inhibitors, or vehicle control at 37°C or RT for indicated times and then were lysed with equal volumes of 2× NP40 lysis buffer (100 mM Tris, pH 7.4, 2% NP40, 20 mM MgCl₂, 300 mM NaCl, 2 mM PMSF, 2 mM NαF, and 2 mM NaVO₄) containing protease inhibitor cocktail tablets on ice for 30 minutes. After centrifugation at 17,000 g and 4°C for 10 minutes, the supernatants were immunoprecipitated with different antibodies overnight. After incubation with Protein A/G PLUS-Agarose beads at 4°C for 2 hours (Santa Cruz Biotechnology Inc.), the beads were analyzed by immunoblotting.

**Platelet life span analysis.** Mice were intravenously injected with 600 μg NHS-biotin in buffer containing 140 mM NaCl and 10% DMSO. Mice were anesthetized with 2.5% tribromoethanol (0.15 ml/10 g), and whole blood was collected by capillary tube from the retroorbital venous plexus at various time points and mixed with ACD. Whole blood (5 μl) was diluted with MTB (45 μl) and stained by PE anti-mouse CD41 antibody (1 μl) and FITC-streptavidin (2.5 μl) at RT for 1 hour. The percentage of biotinylated platelets was determined by flow cytometry.

**Platelet aggregation.** Platelet aggregation was recorded in a CHRONO-LOG lumi-aggregometer. PRP or washed platelets (3 × 10⁹/ml) were incubated with different concentrations of forskolin or vehicle (DMSO) at 22°C for 30 minutes or 72 hours. The pretreated PRP or washed platelets were stimulated with agonists. Platelet aggregation was monitored continuously over 5 to 10 minutes.

**Platelet activation.** Platelet activation was detected by P-selectin (CD62-P) surface exposure and integrin αIIbβ₃ activation. Washed platelets in MTB (3 × 10⁹/ml) were incubated with or without thrombin or vehicle control at 37°C for 30 minutes. The treated platelets were incubated with FITC-labeled anti-CD62-P antibody or FITC-labeled PAC-1 at RT for 20 minutes in the dark and then subjected to flow cytometry analysis.

**In vivo thrombosis.** The ferric chloride–induced (FeCl₃-induced) mesenteric arteriole thrombosis model was used. Briefly, washed mouse platelets were labeled with calcein-AM (5 μg/ml) and incubated with H89 (25 μM), forskolin (5 μM), or vehicle (DMSO) at 22°C for 30 minutes or 72 hours. The recipient male mice were anesthetized, and the mesentery vascular bed was exteriorized. One arteriole was chosen and visualized with an inverted fluorescent microscope (Leica Microsystems) and recorded on videotape. The mice were injected intravenously with pretreated platelets (5×10⁹/g). Thrombus formation was induced by topical application of 3 mm² of filter paper soaked with 5% FeCl₃.

**Statistics.** All data are expressed as mean ± SD. Numeric data were analyzed using 1-way (for single variant) or 2-way (for multiple variants) ANOVA followed by Bonferroni’s adjustment for multiple comparisons. Two groups were compared using 2-tailed Student’s t test. The significance of data was assessed using GraphPad Prism 5 software. Differences were considered as significant at P < 0.05. All experiments requiring the use of animals were subject to randomization based on litter. No animals or samples were excluded from the study. Sample size was predetermined based on the variability observed in prior experiments and on preliminary data. Investigators were not blinded to outcome assessment.

**Study approval.** All animal experiments were approved by the Ethics Committee of The First Affiliated Hospital of Soochow University. Approval to obtain whole blood samples from healthy volunteers and patients was obtained from the Ethics Committee of the First Affiliated Hospital of Soochow University, and written informed consent was obtained from all subjects according to the Declaration of Helsinki.

**Author contributions**
Lili Zhao, JL, CH, and RY designed and performed research and collected, analyzed, and interpreted results. KZ, QC, XM, XL, YZ (9th author), MC, YL, and YN performed animal experiments. JL, YZ (9th author), RH, LC, Ling Zhou, Yunxiao Zhao, and WX performed experimental analysis for patients. Lili Zhao, RY, QC, YZ (11th author), JT, and XM performed mechanistic experiments of apoptosis. CH, Lian Zhao, JL, RH, JT, and MC performed bacterial experiments; AL provided Bad⁻/⁻ mice; CR analyzed data. KD initiated and supervised the project, designed research, analyzed and interpreted results, and wrote the paper.

**Acknowledgments**
This work was supported by grants from the Key Program of the National Natural Science Foundation of China (81130008 to KD), the National Natural Science Foundation of China (81570102 to KD and 81500093 to Lili Zhao), the National Key Basic Research Program of China (2012CB526600 to KD), the NIH (R35GM122457), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Jiangsu Provincial Special Program of Medical Science (BL2012005), the Jiangsu Province’s Key Medical Center (ZX201102), and the Jiangsu Province’s Outstanding Medical Academic Leader Program (to KD).

Address correspondence to: Kesheng Dai, Jiangsu Institute of Hematology, The First Affiliated Hospital and Collaborative Innovation Center of Hematology, Soochow University, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Suzhou 215006, China. Phone: 86.512.67781370; Email: kdai@suda.edu.cn.


The Journal of Clinical Investigation

RESEARCH ARTICLE